Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.fda.gov › safety › recallsRecalls, Market Withdrawals, & Safety Alerts | FDA

   www.fda.gov › safety › recalls

   • Αποθηκευμένο αντίγραφο

   1 Οκτ 2024 · Recalls, Market Withdrawals, & Safety Alerts. The list below provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all...

   • Enforcement Reports

     Separate from determining whether a firm’s action meets the...

   • Industry Guidance For Recalls

     The .gov means it’s official. Federal government websites...

   • Major Product Recalls

     Recalls associated with Almark’s recall of hard-boiled egg...

   • Archive for Recalls, Market Withdrawals & Safety Alerts

     The Recalls, Market Withdrawals & Safety Alerts are...

2. s3-us-west-2.amazonaws.com › drugbank › cite_thisexanta (ximelagatran) tablets nda 21-686 fda advisory committee...

   s3-us-west-2.amazonaws.com › drugbank › cite_this

   EXANTA® (ximelagatran) Tablets NDA 21-686 FDA Advisory Committee Briefing Document 2 EXECUTIVE SUMMARY New Drug Application (NDA) 21-686, submitted by AstraZeneca LP (AstraZeneca), requests approval for the use of EXANTA® (ximelagatran) Tablets as: œ An oral 24-mg twice daily (bid) fixed dose for the long-term secondary prevention

3. www.epistemonikos.org › documents › d5cbed3121495cc3f3b87d547686e3b092d4cdc8EXANTA® (ximelagatran) Tablets NDA 21-686 FDA Advisory Committee...

   www.epistemonikos.org › documents › d5cbed3121495cc3f3b87d547686e3b092d4cdc8

   • Αποθηκευμένο αντίγραφο

   New Drug Application (NDA) 21-686, submitted by AstraZeneca LP (AstraZeneca), requests approval for the use of EXANTA® (ximelagatran) Tablets as: An oral 24-mg twice daily (bid) fixed dose for the long-term secondary prevention of venous thromboembolism (VTE) after standard treatment for an episode of acute VTE An oral 36-mg bid fixed dose ...

4. www.drugs.com › history › exantaExanta (ximelagatran): What is it and is it FDA approved ... -...

   www.drugs.com › history › exanta

   • Αποθηκευμένο αντίγραφο

   Exanta FDA Approval Status. FDA Approved: No. Brand name: Exanta. Generic name: ximelagatran. Company: AstraZeneca. Treatment for: Prevention of Thromboembolism in Atrial Fibrillation. Exanta (ximelagatran) is an investigational oral direct thrombin inhibitor (oral DTI) intended for use in the prevention of strokes in patients with atrial ...

5. www.fda.gov › drugs › news-events-human-drugsUnderstanding Drug Recalls with Dr. Ileana Elder | FDA

   www.fda.gov › drugs › news-events-human-drugs

   • Αποθηκευμένο αντίγραφο

   29 Οκτ 2024 · Dr. Elder: Yes. A class I recall is the most serious, where there is a reasonable probability that using or being exposed to the recalled drug will cause serious adverse health consequences for a ...

6. en.wikipedia.org › wiki › XimelagatranXimelagatran - Wikipedia

   en.wikipedia.org › wiki › Ximelagatran

   • Αποθηκευμένο αντίγραφο

   Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin [1] that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy.

7. www.fda.gov › drugs › drug-safety-and-availabilityDrug Recalls | FDA - U.S. Food and Drug Administration

   www.fda.gov › drugs › drug-safety-and-availability

   • Αποθηκευμένο αντίγραφο

   FDA provides a searchable list of recalled products. Drug recalls are actions taken by a firm to remove a product from the market and may be conducted on a firm's own initiative, by FDA...